Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis Expands Array Service Contract With EPA; Payday May Increase to $6.7M

NEW YORK, Sept. 13 (GenomeWeb News) - The US Environmental Protection Agency has extended and expanded it contract with Expression Analysis to include "additional services and technologies" developed by the company, which will increase the total potential value of the deal to the company by around $4.2 million, the firm said today.


According to the microarray genetics testing and analysis company, the original contract, for $1.5 million, can be extended for two additional option years at $1.5 million per year for a maximum value of around $4.5 million.


The expanded contract, for $1.6 million, can also be expanded for two years at $2.6 million for the first option year and $2.5 million for the second option year, bringing to around $6.7 million the total potential revenue for Expression Analysis.


The original deal, in which Expression Analysis uses Affymetrix DNA chips, will be updated to enable EPA researchers to access Expression Analysis' statistical tools such as its Reduction of Invariant Probes, Permutation Analysis of Differential Expression, and "other analysis and normalization methods," the company said. The firm will continue to use Affy arrays for the duration of the expanded contract.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.